Liquidia Corporation Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.66 (market cap $2.40B), while State Street Technology Select Sector SPDR ETF trades at $188.55 (market cap $129.38B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 53.9× Liquidia Corporation Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| LQDA | XLK | |
|---|---|---|
Market Cap | $2.40B | $129.38B |
Volume | 2,857,547 | 6,753,008 |
Sector | Health | Sector/Thematic |
52-Week High | $91.03 | $202.00 |
52-Week Low | $22.02 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLK trades at $196.24, down slightly by 0.06% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF faces concentration concerns despite its tech sector exposure, with recent news highlighting AI-driven opportunities and potential interest rate impacts. Support levels are established at $195 and $194, with resistance at $198 and $199.
The outlook for XLK remains positive given strong AI investment themes and large-cap tech resilience, though risks include Fed rate hike sensitivity and sector concentration. Investor sentiment is mixed, balancing growth potential against macroeconomic headwinds and valuation pressures in the technology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →